A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia.
Autor: | Skelton WP IV; Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Akhavan NN; Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Taylor ZA; Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Nguyen TC; Department of Internal Medicine, University of Central Florida, Orlando, FL, USA., Hassan H; Cancer Specialists of North Florida, Saint Augustine, FL, USA., Townsend TN; Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Pathak P; Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Trikha G; Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Dang NH; Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Dang LH; Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA., Ali A; Department of Internal Medicine, University of Florida, Gainesville, FL, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Case reports in oncological medicine [Case Rep Oncol Med] 2016; Vol. 2016, pp. 6980198. Date of Electronic Publication: 2016 Nov 23. |
DOI: | 10.1155/2016/6980198 |
Abstrakt: | Introduction . Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings. Case Presentation . We present the case of a 74-year-old Caucasian man with CLL who presented with penile gangrene upon initiation of ibrutinib treatment. Our case is the first showing the complication of penile gangrene associated with ibrutinib use. The gangrene was self-limited upon discontinuing ibrutinib. Conclusion . Our finding describes a very rare yet important adverse event associated with ibrutinib use. Competing Interests: The authors declare that they have no competing interests. |
Databáze: | MEDLINE |
Externí odkaz: |